DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Safety and PK Trial With Injectable ZX003 (Risperidone-SABER®) Compared to Risperdal® Consta® in Stable Schizophrenia

Information source: Zogenix, Inc.
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Schizophrenia; Schizoaffective Disorder

Intervention: ZX003 (Risperidone-SABER®) (Drug); Risperdal Consta (Drug); Oral Risperidone (Drug)

Phase: Phase 1

Status: Recruiting

Sponsored by: Zogenix, Inc.

Official(s) and/or principal investigator(s):
David Walling, PhD, Principal Investigator, Affiliation: Collaborative Neuroscience Network

Overall contact:
Amy Werkheiser, MPH, Phone: 484-431-4569, Email: awerkheiser@zogenix.com

Summary

This is an open-label, multiple dose, PK and safety study in patients with chronic, stable schizophrenia or schizoaffective disorder.

Clinical Details

Official title: An Open-Label, Multiple Dose, Safety and Pharmacokinetic Trial With Injectable ZX003 (Risperidone-SABER) Compared to Risperdal Consta in Patients With Chronic, Stable Schizophrenia or Schizoaffective Disorder

Study design: Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: PK profile of ZX003 determined by C max, T max, C min, AUC (0-24h), AUC (0-tau), C avg

Secondary outcome:

Safety and tolerability of ZX003 as measured by assessing adverse events.

Safety and tolerability of ZX003 as measured by assessing laboratory values.

Detailed description: Approximately 75 male and female patients with schizophrenia or schizoaffective disorder on antipsychotic maintenance medication will be enrolled into the study. There will be 4 planned cohorts of 14 patients per cohort. In Cohorts 1-3, patients' planned participation in the study is for a total of approximately 22 weeks, including a Screening period of up to 35 days, and a study treatment period of 120 days (including follow-up). In Cohort 4 planned participation in the study is for a total of approximately 18 weeks including a Screening period of up to 35 days and a study treatment of 92 days (including follow-up).

Eligibility

Minimum age: 18 Years. Maximum age: 60 Years. Gender(s): Both.

Criteria:

Inclusion Criteria:

1. Male or female patients 18 - 60 years of age, inclusive.

2. Diagnosis of schizophrenia, or schizoaffective disorder as per DSM-V criteria in the past 6 months or more, dependent on diagnosis. 3. Currently on maintenance antipsychotic medication (ie, patients treated with antipsychotic medication with stable doses in the 4 weeks prior to Screening and no psychosis-related dose changes in the 8 weeks prior to Screening). 4. Body Mass Index (BMI) ≥20 and ≤40 kg/m2. 5. Female patients who are non-childbearing potential (surgically sterile [hysterectomy]) or post-menopausal ≥2 years; or non-pregnant, non-lactating females of childbearing potential who agree to use medically acceptable forms of birth control (hormonal contraception, abstinence, diaphragm with spermicide, condom with spermicide, or intrauterine device) from Screening until the End-of-Study visit. 6. No clinically significant abnormal laboratory values. 7. No clinically significant findings in the 12-lead ECG. 8. No clinically significant findings from a vital signs measurement. 9. Be informed of the nature of the study and give written consent prior to initiating any study procedure. Exclusion Criteria: 1. Unwilling to provide genotyping (phenotyping) sample for CYP2D6. 2. Have known or suspected carcinoma. 3. Have known presence or history of renal or hepatic insufficiency. 4. Have known history, hypersensitivity or clinically significant idiosyncratic reaction to risperidone, paliperidone, and/or any other drug substance with similar activity. 5. Have a history of alcohol or drug-dependence as per DSM-V criteria during the 6-month period immediately prior to Screening. 6. Have a history of epilepsy or risk of having seizures. 7. Are pregnant, lactating, or likely to become pregnant during the study. 8. Have taken an antipsychotic depot product (including investigational products) within the 60 days prior to Screening. 9. Participated in another clinical trial or received an investigational product within 30 days prior to Screening. 10. Have a positive alcohol breathalyzer test at Screening or Admission. 11. Have a positive Screening test for hepatitis B virus (HBV), hepatitis C virus (HCV), or human immunodeficiency virus (HIV). 12. Have a positive urine drug test (cocaine, amphetamines, barbiturates, opiates, benzodiazepines (unless prescribed), cannabinoids, etc.) at Screening or Admission. 13. Excessive use of caffeine-containing beverages exceeding 500 mg caffeine/day (5 cups of coffee). 14. Use of alcohol or alcohol-containing foods, medications or beverages, within 48 hours prior to Admission. 15. Excessive smoking, defined as smoking more than 2 packs of cigarettes (or 5 cigars) per day for 1 year or greater. 16. Donation of blood (>500 mL) or blood products within 2 months (56 days) prior to Admission. 17. Have used any concomitant medications significantly impacting CYP2D6 (moderate and strong inducers/inhibitors),within 14 days or 5 half-lives (whichever is longer) prior to Admission. Medications judged to not interact with risperidone may be continued at the discretion of the Investigator and in accordance with the protocol requirements for tapering and washout. 18. Are unable to understand the protocol requirements, instructions and study related restrictions, the nature, scope and possible consequences of the clinical study. 19. Are unlikely to comply with the protocol requirements, instructions and study- related restrictions (eg, uncooperative attitude, inability to return for out-patient visits or improbability of completing the clinical study). 20. Are unable to tolerate the Oral Risperidone Challenge

Locations and Contacts

Amy Werkheiser, MPH, Phone: 484-431-4569, Email: awerkheiser@zogenix.com

Collaborative Neuroscience Network, Long Beach, California 90806, United States; Recruiting
Additional Information

Starting date: February 2015
Last updated: July 14, 2015

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017